Sources
Loading...
Additional media
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Xaira Therapeutics, a new artificial intelligence biotech firm, has launched with over $1 billion in funding to revolutionize drug research and development. The startup, spearheaded by former Stanford president Marc Tessier-Lavigne as CEO, boasts a notable board including ex-J&J CEO Alex Gorsky and former FDA head Scott Gottlieb. Investors include prominent firms such as ARCH, Foresite, NEA, F-Prime, Sequoia, Lux, Lightspeed, and Two Sigma. The company aims to leverage RFdiffusion technology from David Baker's lab to reduce attrition in the drug discovery process and is set to operate as a non-profit and open source entity.
The former president of Stanford University is leading a new artificial intelligence drug development startup, with $1 billion in capital commitments from investors https://t.co/m7bSLkfQc5
Given today's Xaira news highlighted few other big VC raises, here's a look at what Altos Labs might be up in their $3bn quest to slow aging. #longevity (thanks @Arjun_J_Kumar). Great work from @AlexJColville. https://t.co/by2ez9PO7n
I am excited about this application of #AI spearheaded by @StephenQuake👇. It can addresses pain point of drug discovery by reducing attrition in drug discovery process. @czbiohub is impressively further along with a laudable goal of making this non-profit & open source. https://t.co/jy6k3W4Zb1